Neurogene Stock Today

NGNE Stock   16.70  0.10  0.60%   

Performance

Very Weak

 
Weak
 
Strong

Odds Of Distress

Low

 
High
 
Low
Neurogene is trading at 16.70 as of the 17th of March 2025, a 0.6 percent decrease since the beginning of the trading day. The stock's lowest day price was 16.46. Neurogene has about a 23 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
7th of March 2014
Category
Healthcare
Classification
Health Care
Neurogene is entity of United States. It is traded as Stock on NASDAQ exchange. The company has 14.83 M outstanding shares of which 1.75 M shares are now shorted by private and institutional investors with about 7.15 trading days to cover. More on Neurogene

Moving against Neurogene Stock

  0.56DMAC DiaMedica Therapeutics Earnings Call TodayPairCorr
  0.55VALN Valneva SE ADR Earnings Call TomorrowPairCorr
  0.49VIGL Vigil NeurosciencePairCorr
  0.38VERV Verve TherapeuticsPairCorr

Neurogene Stock Highlights

ESG Sustainability
Environmental
Governance
Social
CFO PresidentChristine JD
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors)
Average Analyst Recommendation
Financial Strength
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.260.29
Moderately Down
Slightly volatile
Total Current Liabilities27.7 M26.4 M
Sufficiently Up
Slightly volatile
Non Current Liabilities Total14.8 M15.6 M
Notably Down
Slightly volatile
Total Assets155.8 M256 M
Way Down
Pretty Stable
Total Current Assets135.7 M230.4 M
Way Down
Slightly volatile
Debt Levels
Neurogene can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Neurogene's financial leverage. It provides some insight into what part of Neurogene's total assets is financed by creditors.
Liquidity
Neurogene currently holds 16.25 M in liabilities. Note, when we think about Neurogene's use of debt, we should always consider it together with its cash and equity.

Free Cash Flow

(48.9 Million)
Neurogene (NGNE) is traded on NASDAQ Exchange in USA. It is located in 535 W 24th Street, New York, NY, United States, 10011 and employs 91 people. Neurogene is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 593.14 M. Neurogene conducts business under Biotechnology sector and is part of Health Care industry. The entity has 14.83 M outstanding shares of which 1.75 M shares are now shorted by private and institutional investors with about 7.15 trading days to cover. Neurogene generates negative cash flow from operations
Check Neurogene Probability Of Bankruptcy
Ownership Allocation
The majority of Neurogene outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in Neurogene to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in Neurogene. Please pay attention to any change in the institutional holdings of Neurogene as this could imply that something significant has changed or is about to change at the company.
Check Neurogene Ownership Details

Neurogene Historical Income Statement

At present, Neurogene's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Total Other Income Expense Net is expected to grow to about 23.3 M, whereas Operating Income is forecasted to decline to (52.5 M). View More Fundamentals

Neurogene Stock Against Markets

Neurogene Corporate Management

MD MBASenior DevelopmentProfile
Effie MDSenior ResearchProfile
Donna JDSenior CounselProfile
CPI FAAPQuality AffairsProfile
Ricardo JimenezSenior OperationsProfile
When determining whether Neurogene is a strong investment it is important to analyze Neurogene's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Neurogene's future performance. For an informed investment choice regarding Neurogene Stock, refer to the following important reports:
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Neurogene. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
For information on how to trade Neurogene Stock refer to our How to Trade Neurogene Stock guide.
You can also try the Portfolio Manager module to state of the art Portfolio Manager to monitor and improve performance of your invested capital.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Neurogene. If investors know Neurogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Neurogene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.66)
Revenue Per Share
0.106
Return On Assets
(0.32)
Return On Equity
(0.41)
The market value of Neurogene is measured differently than its book value, which is the value of Neurogene that is recorded on the company's balance sheet. Investors also form their own opinion of Neurogene's value that differs from its market value or its book value, called intrinsic value, which is Neurogene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Neurogene's market value can be influenced by many factors that don't directly affect Neurogene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Neurogene's value and its price as these two are different measures arrived at by different means. Investors typically determine if Neurogene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Neurogene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.